Zoely^® is an unique oral combined hormone contraception containing 2.5 mg of Nomegestrol Acetate and 1.5 mg Estradiol (as 17β-estradiol).¹

17β-estradiol is a natural estrogen with a structure that is identical to the estrogen produced in a womans body¹, Nomegestrol Acetate is metabolically neutral without any androgenic, estrogenic or mineralo-glucocorticoid activities.¹

Zoely^®1,3,4

• 4th generation monophasic combined hormone contraceptive pill, containing 24 active (white) pills and 4 placebo (yellow) pills.
• Inhibits ovulation & causes changes in the endometrium.¹
• Has a Pearl index of 0.40. ¹
• Is GMS reimbursed.

Combined oral contraceptives including Zoely^® are suitable for use in the following patient groups^1,3,4

• Women who want autonomy and control over their menstrual cycle.
• Women aged up to 50 years with no other medical conditions.
• Women with a BMI of ≤30kg/m2 who do not smoke.
• Women ≥6 weeks postpartum if not breast feeding.
• Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern.
• Women with endometriosis.

References

1. Zoely® SmPC
2. Chabbert_Buffet N et al., Gynaecol Endocrinol 2013;29 (10) 891 – 96
3. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.
4. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.